Deborah Berg Selected Research

ixazomib

1/2022	A phase 2, open-label, multicenter study of ixazomib plus lenalidomide and dexamethasone in adult Japanese patients with relapsed and/or refractory multiple myeloma.
1/2022	A randomized phase 3 study of ixazomib-dexamethasone versus physician's choice in relapsed or refractory AL amyloidosis.
1/2021	Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.
9/2020	Clinical benefit of ixazomib plus lenalidomide-dexamethasone in myeloma patients with non-canonical NF-κB pathway activation.
7/2020	c-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myeloma.
6/2019	Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies.
1/2019	Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance.
8/2018	Healthcare resource utilization with ixazomib or placebo plus lenalidomide-dexamethasone in the randomized, double-blind, phase 3 TOURMALINE-MM1 study in relapsed/refractory multiple myeloma.
5/2018	Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma.
1/2018	Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Deborah Berg Research Topics

Disease

19	Multiple Myeloma 01/2022 - 08/2014
5	Thrombocytopenia (Thrombopenia) 01/2017 - 08/2014
4	Immunoglobulin Light-chain Amyloidosis 01/2022 - 01/2015
4	Neoplasms (Cancer) 01/2021 - 06/2015
3	Exanthema (Rash) 01/2018 - 08/2014
3	Peripheral Nervous System Diseases (PNS Diseases) 01/2018 - 08/2014
3	Fatigue 06/2015 - 08/2014
2	Disease Progression 06/2019 - 08/2018
2	Neutropenia 12/2014 - 08/2014
2	Nausea 08/2014 - 08/2014
1	Chromosome Aberrations (Chromosome Abnormalities) 01/2017
1	Hematologic Neoplasms (Hematological Malignancy) 06/2015
1	Lymphoma (Lymphomas) 06/2015
1	Skin Diseases (Skin Disease) 12/2014
1	Vomiting 08/2014
1	Diarrhea 08/2014
1	Candidiasis (Moniliasis) 04/2010
1	Infections 04/2010
1	Coccidioidomycosis 06/2005
1	Colorectal Neoplasms (Colorectal Cancer) 11/2003

Drug/Important Bio-Agent (IBA)

20	ixazomibIBA 01/2022 - 08/2014
17	Lenalidomide (CC 5013)FDA Link 01/2022 - 08/2014
16	Dexamethasone (Maxidex)FDA LinkGeneric 01/2022 - 12/2014
12	Proteasome InhibitorsIBA 06/2019 - 08/2014
6	Pharmaceutical PreparationsIBA 01/2018 - 11/2003
4	Bortezomib (Velcade)FDA Link 10/2017 - 08/2014
2	Thalidomide (Thalomid)FDA Link 01/2022 - 08/2014
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2022 - 06/2019
2	Proteasome Endopeptidase Complex (Proteasome)IBA 06/2015 - 08/2014
1	Prednisone (Sone)FDA LinkGeneric 06/2019
1	Inosine Monophosphate (IMP)IBA 06/2019
1	Melphalan (Alkeran)FDA LinkGeneric 06/2019
1	Immunomodulating AgentsIBA 10/2017
1	Immunoglobulin Light Chains (Immunoglobulin Light Chain)IBA 01/2017
1	Amyloid (Amyloid Fibrils)IBA 01/2015
1	marizomibIBA 08/2014
1	carfilzomibIBA 08/2014
1	Antifungal AgentsIBA 04/2010
1	posaconazole FDA Link 06/2005
1	PlatinumIBA 11/2003
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 11/2003
1	Fluorouracil (Carac)FDA LinkGeneric 11/2003
1	Leucovorin (Folinic Acid)FDA Link 11/2003

Therapy/Procedure

15	Therapeutics 07/2020 - 06/2005
2	Drug Therapy (Chemotherapy) 01/2017 - 11/2003
1	Stem Cell Transplantation 07/2020
1	Transplantation 06/2019
1	Art Therapy 04/2010
1	Aftercare (After-Treatment) 06/2005
1	Salvage Therapy 06/2005